CRISPR Therapeutics AG (CRSP)

CRISPR Therapeutics AG's Q·Score is 5.2/10 (Bearish), reflecting its current fundamentals, analyst data, and valuation metrics. Clean balance sheet with low leverage (0.1× debt-to-equity). Key area to monitor: low return on equity (-30%). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.

The consensus price target for CRSP is $83.35, based on ratings from 23 Wall Street analysts. This is 61.4% above the current price of $51.63. Price targets are forward-looking estimates and not guarantees of future performance.

CRISPR Therapeutics AG (CRSP) scores in line with sector averages on valuation metrics. The consensus analyst price target of $83.35 is 61% above the current price.

CRISPR Therapeutics AG is scheduled to report earnings in 8 days, on May 11, 2026.

CRISPR Therapeutics AG has a net profit margin of 0.0%, indicating the company is currently operating at a net loss. Its gross margin stands at 0.0%, reflecting a more cost-intensive business model.

CRISPR Therapeutics AG is reporting revenue declining 97.6% year-over-year.

CRISPR Therapeutics AG has a debt-to-equity ratio of 0.11×, reflecting a very low debt-to-equity ratio, signalling a conservatively financed balance sheet. Its current ratio is 13.32×, indicating comfortable short-term liquidity.